What has kept biogenerics legislation from being passed in the United States up until now?
Several bills have been introduced over the last two years, but some were very pro-proprietary biotech and pro-branded pharma. The language in these bills discouraged competition in the generic biologics space and contained numerous provisions that would ultimately delay the entry of generic biologics in the U.S. or lessen their impact.
